# Diaceutics PLC 43.9% potential upside indicated by Canaccord Genuity

- Link: https://www.directorstalkinterviews.com/diaceutics-plc-43.9-potential-upside-indicated-by-canaccord-genuity/4121148753
- Published: 2024-03-22T13:57:57+00:00
- Author: Charlotte Edwards

**Diaceutics PLC** with ticker (LON:DXRX) now has a potential upside of 43.9% according
to Canaccord Genuity.
Canaccord Genuity set a target price of 150 GBX for the company,
which when compared to the Diaceutics PLC share price of 104 GBX at opening today(
22/03/2024) indicates a potential upside of 43.9%. Trading has ranged between 79(
52 week low) and 110 (52 week high) with an average of 42,038 shares exchanging 
hands daily. The market capitalisation at the time of writing is £88,296,393.Diaceutics
PLC is a United Kingdom-based company, which is a provider of technology and solutions.
The Company provides pharma and biotech companies with an end-to-end commercialization
solution for precision medicine through data analytics, scientific and advisory 
services enabled by its platform DXRX – The Diagnostics Network. The Company operates
through three segments: Insight Solutions (Data), Engagement Solutions (Tech enabled
services), and Advisory Services (Professional services). The Company’s DXRX – The
Diagnostics Network is a diagnostic commercialization platform for precision medicine,
integrating multiple pipelines of real-world diagnostic testing data from a global
network of laboratories. It provides unrivalled access to multiple pipelines of 
real-world diagnostic testing data from a global network of laboratories. Its Tech
Enabled Services offers clinical testing labs to provide enablement and educational
services in novel biomarkers.

Share on:
